Dawn F. Ionescu

Efficacy and Safety of the Selective, Brain-Penetrant P2X7 Receptor Antagonist JNJ-55308942 (Zanvipixant) in Bipolar Depression: A Phase 2a Study.

Journal: Biological psychiatry global open science

Published: January 27, 2026

Effects of esketamine on patient-reported outcomes in major depressive disorder with active suicidal ideation and intent: a pooled analysis of two randomized phase 3 trials (ASPIRE I and ASPIRE II).

Journal: Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation

Published: May 24, 2023

Effect of Concomitant Benzodiazepines on the Antidepressant Effects of Ketamine: Findings From the RAPID Intravenous Ketamine Study.

Journal: The Journal of clinical psychiatry

Published: November 16, 2022

Esketamine Nasal Spray for the Rapid Reduction of Depressive Symptoms in Major Depressive Disorder With Acute Suicidal Ideation or Behavior.

Journal: Journal of clinical psychopharmacology

Published: August 19, 2021

The effect of single administration of intravenous ketamine augmentation on suicidal ideation in treatment-resistant unipolar depression: Results from a randomized double-blind study.

Journal: European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology

Published: February 10, 2021

The effect of esketamine in patients with treatment-resistant depression with and without comorbid anxiety symptoms or disorder.

Journal: Depression and anxiety

Published: December 23, 2020

Monitoring Changes in Depression Severity Using Wearable and Mobile Sensors.

Journal: Frontiers in psychiatry

Published: July 17, 2020

Studying pre-treatment and ketamine-induced changes in white matter microstructure in the context of ketamine's antidepressant effects.

Journal: Translational psychiatry

Published: June 23, 2020

Esketamine Nasal Spray for Rapid Reduction of Depressive Symptoms in Patients With Major Depressive Disorder Who Have Active Suicide Ideation With Intent: Results of a Phase 3, Double-Blind, Randomized Study (ASPIRE II).

Journal: The international journal of neuropsychopharmacology

Published: April 07, 2020

Esketamine Nasal Spray for Rapid Reduction of Major Depressive Disorder Symptoms in Patients Who Have Active Suicidal Ideation With Intent: Double-Blind, Randomized Study (ASPIRE I).

Journal: The Journal of clinical psychiatry

Published: December 02, 2019

Time to relapse after a single administration of intravenous ketamine augmentation in unipolar treatment-resistant depression.

Journal: Journal of affective disorders

Published: April 29, 2019

Perinatal depressive symptoms often start in the prenatal rather than postpartum period: results from a longitudinal study.

Journal: Archives of women's mental health

Published: January 18, 2019

Efficacy and Safety of the Selective, Brain-Penetrant P2X7 Receptor Antagonist JNJ-55308942 (Zanvipixant) in Bipolar Depression: A Phase 2a Study.

Efficacy and Safety of the Selective, Brain-Penetrant P2X7 Receptor Antagonist JNJ-55308942 (Zanvipixant) in Bipolar Depression: A Phase 2a Study.

Effects ﻿of esketamine on patient-reported outcomes in major depressive disorder with active suicidal ideation and intent: a pooled analysis of two randomized phase 3 trials (ASPIRE I and ASPIRE II).

Effects ﻿of esketamine on patient-reported outcomes in major depressive disorder with active suicidal ideation and intent: a pooled analysis of two randomized phase 3 trials (ASPIRE I and ASPIRE II).

Effect of Concomitant Benzodiazepines on the Antidepressant Effects of Ketamine: Findings From the RAPID Intravenous Ketamine Study.

Effect of Concomitant Benzodiazepines on the Antidepressant Effects of Ketamine: Findings From the RAPID Intravenous Ketamine Study.

Esketamine Nasal Spray for the Rapid Reduction of Depressive Symptoms in Major Depressive Disorder With Acute Suicidal Ideation or Behavior.

Esketamine Nasal Spray for the Rapid Reduction of Depressive Symptoms in Major Depressive Disorder With Acute Suicidal Ideation or Behavior.

The effect of single administration of intravenous ketamine augmentation on suicidal ideation in treatment-resistant unipolar depression: Results from a randomized double-blind study.

The effect of single administration of intravenous ketamine augmentation on suicidal ideation in treatment-resistant unipolar depression: Results from a randomized double-blind study.

The effect of esketamine in patients with treatment-resistant depression with and without comorbid anxiety symptoms or disorder.

The effect of esketamine in patients with treatment-resistant depression with and without comorbid anxiety symptoms or disorder.

Monitoring Changes in Depression Severity Using Wearable and Mobile Sensors.

Monitoring Changes in Depression Severity Using Wearable and Mobile Sensors.

Studying pre-treatment and ketamine-induced changes in white matter microstructure in the context of ketamine's antidepressant effects.

Studying pre-treatment and ketamine-induced changes in white matter microstructure in the context of ketamine's antidepressant effects.

Esketamine Nasal Spray for Rapid Reduction of Depressive Symptoms in Patients With Major Depressive Disorder Who Have Active Suicide Ideation With Intent: Results of a Phase 3, Double-Blind, Randomized Study (ASPIRE II).

Esketamine Nasal Spray for Rapid Reduction of Depressive Symptoms in Patients With Major Depressive Disorder Who Have Active Suicide Ideation With Intent: Results of a Phase 3, Double-Blind, Randomized Study (ASPIRE II).

Esketamine Nasal Spray for Rapid Reduction of Major Depressive Disorder Symptoms in Patients Who Have Active Suicidal Ideation With Intent: Double-Blind, Randomized Study (ASPIRE I).

Esketamine Nasal Spray for Rapid Reduction of Major Depressive Disorder Symptoms in Patients Who Have Active Suicidal Ideation With Intent: Double-Blind, Randomized Study (ASPIRE I).

Time to relapse after a single administration of intravenous ketamine augmentation in unipolar treatment-resistant depression.

Time to relapse after a single administration of intravenous ketamine augmentation in unipolar treatment-resistant depression.

Perinatal depressive symptoms often start in the prenatal rather than postpartum period: results from a longitudinal study.

Perinatal depressive symptoms often start in the prenatal rather than postpartum period: results from a longitudinal study.

Effects of esketamine on patient-reported outcomes in major depressive disorder with active suicidal ideation and intent: a pooled analysis of two randomized phase 3 trials (ASPIRE I and ASPIRE II).

Effects of esketamine on patient-reported outcomes in major depressive disorder with active suicidal ideation and intent: a pooled analysis of two randomized phase 3 trials (ASPIRE I and ASPIRE II).